Immuno-Oncology

The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of adjuvant anti–PD-L1 agents on the treatment landscape of melanoma.

Treatment with nivolumab reduced the risk of death by 32% compared with investigator’s choice of therapy for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the results of a study investigating durvalumab (Imfinzi) plus tremelimumab in patients with metastatic urothelial cancer.

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

The FDA has approved the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced renal cell carcinoma.

Adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma, according to phase III results from the EORTC 1325-MG/KEYNOTE-054 trial.

Durvalumab treatment over 12 months had no negative effect on key symptoms of lung cancer, physical function, global health status, or quality of life in patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following concurrent chemoradiotherapy.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.

The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.

Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.

Andrew Ko, MD, discusses how the approval of pembrolizumab has impacted patients with positive PD-L1 expression and how clinical trials that have reshaped the standard of care in patients with gastric and GEJ cancers.

Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.

Amit Gupta, MD, discusses the superiority of robotic cystectomy compared with open cystectomies and its relevance in the current treatment landscape of bladder cancer.

Single-agent treatment with the PD-1 inhibitor pembrolizumab improved overall survival versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer and a PD-L1 expression level ≥1%.

Zev A. Wainberg, MD, discusses data from the pancreatic cancer cohort of a trial evaluating cabiralizumab in combination with nivolumab.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing adverse events (AEs) of immunotherapy in lung cancer.